Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $69.13 Analyst target: $154.72 Upside: 123.81%
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in Minneapolis, Minnesota.
See the full interactive analysis & chart →Informational only — not investment advice.